--- title: Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol nct_id: NCT03263299 overall_status: UNKNOWN phase: PHASE4 sponsor: Cairo University study_type: INTERVENTIONAL primary_condition: Invitro Fertilization countries: Egypt canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03263299.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03263299" ct_last_update_post_date: 2017-08-28 last_seen_at: "2026-05-12T06:37:00.185Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol **Official Title:** Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET Using Microdose GnRH Agonist Flare-Up-Protocol **NCT ID:** [NCT03263299](https://clinicaltrials.gov/study/NCT03263299) ## Key Facts - **Status:** UNKNOWN - **Phase:** PHASE4 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 120 - **Lead Sponsor:** Cairo University - **Conditions:** Invitro Fertilization - **Start Date:** 2017-08 - **Completion Date:** 2018-09 - **CT.gov Last Update:** 2017-08-28 ## Brief Summary Ovarian stimulation will be done using the Microdose flare-up regimen. The patient will receive diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation will be initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day. Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) will be injected when at least 2 follicles 18 mm were observed on ultrasonography. Oocytes willbe retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding. After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization. The luteal phase support will be initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done. ## Detailed Description Ovarian stimulation was done using the Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day. Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) were injected when at least 2 follicles 18 mm were observed on ultrasonography. Oocytes were retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding. After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization. The luteal phase support was initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done. Serum β-hCG was performed 14 days after the embryo transfer to confirm chemical pregnancy. Clinical pregnancy was confirmed when there was an evidence of gestational sac, embryo and fetal heart activity at time of transvaginal ultrasound evaluation by the 6th week. ## Eligibility - **Minimum age:** 20 Years - **Maximum age:** 39 Years - **Sex:** FEMALE - **Healthy Volunteers:** No ``` Inclusion Criteria: 1. Patients with a history of one or more failed IVF cycles with three or less retrieved oocytes 2. No age limitation 3. Patients with an inadequate ovarian response in previous cycle 4. Low estradiol (E2) levels in response to ovarian stimulation in previous cycle 5. Lower number of retrieved oocytes in previous trials. Exclusion Criteria: 1. Severe male factor (azospermia) 2. Hydrosalpinx 3. History of endometriosis 4. Endocrine or metabolic disorders 5. Follicle stimulating hormone (FSH) level \> 15 mIU. 6. Antimullerian hormone (AMH)\< 0.5 ng/ml 7. Any uterine causes of infertility e.g. septate uterus ``` ## Arms - **cabergoline group** (ACTIVE_COMPARATOR) — received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide - **Aspirin group** (ACTIVE_COMPARATOR) — Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide - **GnRH Group** (ACTIVE_COMPARATOR) — Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day. ## Interventions - **cabergoline** (DRUG) — Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer - **Aspirin** (DRUG) — Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide - **GnRH agonist** (DRUG) — Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day. ## Primary Outcomes - **clinical pregnancy** _(time frame: 4 weeks after embryo transfer)_ — Intrauterine gestational sac detection by transvaginal ultrasound ## Locations (1) - Kasr Alainy medical school, Cairo, Egypt ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.kasr alainy medical school|cairo||egypt` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT03263299.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT03263299* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*